Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112.

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.

Author information

1
Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Children's Hospital Los Angeles, MS#57, Los Angeles, CA 90027, USA. fmuckun@chla.usc.edu

Abstract

Spleen tyrosine kinase (SYK) has emerged as a potential molecular target for the treatment of B-lineage leukemias and lymphomas. Here, we provide an overview of the current state of knowledge regarding the regulatory signaling function of SYK and its role in the pathogenesis of B-lineage lymphoid malignancies, available methods and drug candidates for targeting SYK, as well as compelling preclinical and clinical evidence regarding the clinical potential of inhibiting SYK. The further development of rationally designed SYK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias and lymphomas.

PMID:
20836676
DOI:
10.1586/era.10.112
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center